INSD; MZKR Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Instadose Pharma Corp. f/k/a Mikrocoze, Inc. Shareholders of Class Action and Lead Deadline: February 28, 2022

If you wish to review a copy of the Complaint you can visit the firms site: www.bgandg.com/insd or you may contact Peretz Bronstein, Esq.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, January 13, 2022
Information
Tags: 
Legal, Professional Services, Court, Risk, Review, LLC, Lists of schools in England, Complaint, Business architecture, Company
Geotags: 
NEW YORK
⚠generated by AI ↴
Summary
Key Points: 
  • If you wish to review a copy of the Complaint you can visit the firms site: www.bgandg.com/insd or you may contact Peretz Bronstein, Esq.
  • or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Instadose you have until February 28, 2022, to request that the Court appoint you as lead plaintiff.
  • In addition to representing institutions and other investor plaintiffs in class action security litigation, the firms expertise includes general corporate and commercial litigation, as well as securities arbitration.


Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Instadose Pharma Corp. f/k/a Mikrocoze, Inc. ("Instadose", "Mikrocoze", or the "Company") (OTCMKTS: INSD; MZKR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Instadose securities between December 8, 2020 and November 24, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/insd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Instadose had performed inadequate due diligence into the Business Combination and/or ignored significant red flags associated with Instadose Canada; (2) Instadose's internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (3) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/insd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Instadose you have until February 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright: 
Copyright Business Wire 2022